Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pneumocystis carinii pneumonia recurrence in HIV patients on highly activeantiretroviral therapy: Secondary prophylaxis
Autore:
Abgrall, S; Matheron, S; Le Moing, V; Dupont, C; Costagliola, D;
Indirizzi:
Fac Med St Antoine, INSERM, SC4, F-75571 Paris 12, France Fac Med St Antoine Paris France 12 INSERM, SC4, F-75571 Paris 12, France Hop Bichat Claude Bernard, F-75877 Paris, France Hop Bichat Claude Bernard Paris France F-75877 rd, F-75877 Paris, France Hop Ambroise Pare, Boulogne, France Hop Ambroise Pare Boulogne FranceHop Ambroise Pare, Boulogne, France
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 2, volume: 26, anno: 2001,
pagine: 151 - 158
SICI:
1525-4135(20010201)26:2<151:PCPRIH>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-IMMUNODEFICIENCY-VIRUS; DISCONTINUATION; INFECTION; DISEASE; CHEMOPROPHYLAXIS; MORTALITY; RECOVERY; HAART;
Keywords:
HIV infection; Pneumocystis carinii pneumonia; risk factors; maintenance prophylaxis; CD4; antiretroviral therapy; observational study;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Abgrall, S Fac Med St Antoine, INSERM, SC4, 27 Rue Chalingy, F-75571 Paris12, France Fac Med St Antoine 27 Rue Chalingy Paris France 12 12, France
Citazione:
S. Abgrall et al., "Pneumocystis carinii pneumonia recurrence in HIV patients on highly activeantiretroviral therapy: Secondary prophylaxis", J ACQ IMM D, 26(2), 2001, pp. 151-158

Abstract

The incidence and risk factors for Pneumocystis carinii pneumonia (PCP) recurrence were evaluated in 451 HIV-infected patients enrolled in the FrenchHospital Database on HIV who starred highly active antiretroviral therapy (HAART) while receiving secondary PCP prophylaxis after a first episode occurring between January 1995 and December 1998. There were 18 episodes of recurrent PCP. On HAART, the CD4(+) cell count increased to above 200 x 10(6)/L in 274 patients, 51 of whom stopped PCP prophylaxis. None of these patients had PCP recurrences during 363 person-years (PY) of follow-up after theCD4+ cell count had reached 200 x 10(6)/L (incidence rate [IR], 0.00 cases/100 PY; 95% confidence interval [CI], 0.00-0.82), and 37 PY of follow-up after the CD4(+) cell count had reached 200 x 10(6)/L and PCP prophylaxis had been discontinued (IR, 0.00 cases/100 PY; 95% CI, 0.00-7.84). The CD4(+) cell count remained < 200 x 106/L in 177 patients; 9 patients stopped PCP prophylaxis, and 6 of these had a disease recurrence. Multivariate Cox analysis (time censored when CD4+ cell count > 200 x 10(6)/L) showed that discontinuation of secondary prophylaxis (relative hazard [RH], 25.95; p < .0001)was associated with recurrence, whereas higher CD4+ cell counts during follow-up (RH, 0.39/50 x 10(6)/L increment; p < .002) were protective.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 22:47:32